Back to results

CompletedPhase 2

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

NCT02695420

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Kasugai-shi, Aichi-ken, Japan

+31 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2016-04-14
Enrollment: 81 participants
Sponsor: Cytokinetics
Purpose: treatment

Locations (32)

Research SiteKasugai-shi, Aichi-ken, Japan
Research SiteKasugai-shi, Aichi-ken, Japan
Research SiteNagoya, Aichi-ken, Japan
Research SiteAsahi-shi, Chiba, Japan
Research SiteChiba, Chiba, Japan
Research SiteImabari, Ehime, Japan
Research SiteChikushino-shi, Fukuoka, Japan
Research SiteFukuoka, Fukuoka, Japan
Research SiteFukuoka, Fukuoka, Japan
Research SiteHakodate-shi, Hokkaido, Japan
Research SiteSapporo, Hokkaido, Japan
Research SiteAmagasaki-shi, Hyōgo, Japan
Research SiteKawanishi-shi, Hyōgo, Japan
Research SiteTakarazuka-shi, Hyōgo, Japan
Research SiteKanazawa, Ishikawa-ken, Japan
Research SiteNankoku-shi, Kochi, Japan
Research SiteŌita, Oita Prefecture, Japan
Research SiteOkayama, Okayama-ken, Japan
Research SiteKishiwada-shi, Osaka, Japan
Research SiteOsaka, Osaka, Japan
Research SiteOsaka, Osaka, Japan
Research SiteOsaka, Osaka, Japan
Research SiteSuita-shi, Osaka, Japan
Research SiteSaga, Saga-ken, Japan
Research SiteSaitama-shi, Saitama, Japan
Research SiteWako-shi, Saitama, Japan
Research SiteSunto-gun, Shizuoka, Japan
Research SiteChiyoda-ku, Tokyo, Japan
Research SiteItabashi-ku, Tokyo, Japan
Research SiteItabashi-ku, Tokyo, Japan
Research SiteMeguro-ku, Tokyo, Japan
Research SiteShinagawa-ku, Tokyo, Japan

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction — TrialFind